Le Lézard
Classified in: Health
Subject: FDA

Teligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2%

BUENA, N.J., July 21, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Erythromycin Topical Gel USP, 2%.  This is Teligent's third approval for 2017, and its fourteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. 

Teligent, Inc. Logo (PRNewsFoto/IGI Laboratories, Inc.)

Based on recent QuintilesIMS Health data from May 2017, the total addressable market for this product is approximately $17.6 million.

"Erythromycin Topical Gel USP, 2% is Teligent's third FDA approval in 2017,'' commented Jason Grenfell-Gardner, President and CEO of the Company. "Teligent now has nineteen topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products. We expect to launch this product in the third quarter of 2017."

About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company.  Our mission is to be a leading player in the specialty generic prescription drug market.  Learn more on our website www.teligent.com.

Forward-Looking Statements
This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue," "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions.  These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in Teligent, Inc.'s most recent Annual Report on Form 10-K,  Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission.  Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.


Jenniffer Collins

Teligent, Inc.

(856) 697-4379



SOURCE Teligent, Inc.

These press releases may also interest you

at 00:19
Erie Meat Products Ltd. is recalling Butcher's Selection brand Stampede Chicken Burgers from the marketplace because they may contain egg which is not declared on the label. People with an allergy to egg should not consume the recalled product...

16 mar 2018
Constellation Healthcare Technologies, Inc. ("Constellation" or "the Company"), a healthcare services organization providing outsourced revenue cycle management, practice management, and group purchasing services to U.S. physicians, along with...

16 mar 2018
The Spice Tailor (Canada) Limited is recalling The Spice Tailor brand Fiery Goan Curry from the marketplace because it contains mustard which is not declared on the label. People with an allergy to mustard should not consume the recalled product...

16 mar 2018
The "Cleanroom Technology Market by Type (Consumables, Equipment), by Construction, by End User, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023" report has been added to ResearchAndMarkets.com's offering....

16 mar 2018
"The CAP applauds the Centers for Medicare & Medicaid Services (CMS) for revising its final national coverage determination (NCD) policy for next-generation sequencing (NGS) to address some of the concerns raised by the CAP and other stakeholders....

16 mar 2018
The "Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018" report has been added to ResearchAndMarkets.com's offering. The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018...

News published on 21 july 2017 at 08:00 and distributed by: